Summit Therapeutics (SMMT) Equity Average (2020 - 2025)
Summit Therapeutics (SMMT) has disclosed Equity Average for 6 consecutive years, with $225.9 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 28.64% year-over-year to $225.9 million, compared with a TTM value of $225.9 million through Sep 2025, down 28.64%, and an annual FY2024 reading of $233.2 million, up 128.26% over the prior year.
- Equity Average was $225.9 million for Q3 2025 at Summit Therapeutics, down from $301.9 million in the prior quarter.
- Across five years, Equity Average topped out at $413.3 million in Q4 2024 and bottomed at $57.9 million in Q2 2022.
- Average Equity Average over 5 years is $156.9 million, with a median of $110.9 million recorded in 2021.
- The sharpest move saw Equity Average crashed 53.14% in 2024, then soared 501.37% in 2025.
- Year by year, Equity Average stood at $92.8 million in 2021, then soared by 40.05% to $130.0 million in 2022, then tumbled by 31.87% to $88.5 million in 2023, then soared by 366.86% to $413.3 million in 2024, then plummeted by 45.36% to $225.9 million in 2025.
- Business Quant data shows Equity Average for SMMT at $225.9 million in Q3 2025, $301.9 million in Q2 2025, and $366.5 million in Q1 2025.